Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Frequently asked questions
What sector does Rallybio Corp (RLYB) operate in?
Rallybio Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Rallybio Corp (RLYB) current stock price?
As of the latest data, Rallybio Corp stock price is $16.65, with a previous close of $16.49. Rallybio Corp gained $0.16 in the last trading session, representing a 0.97% increase.
What is Rallybio Corp (RLYB) current market capitalization?
Rallybio Corp market cap is approximately 88.45 million.
What is Rallybio Corp (RLYB) Earnings Per Share (EPS)?
The trailing EPS is $8.12, and the forward EPS is -$3.60.
What is Rallybio Corp (RLYB) Price-to-Earnings (P/E) ratio?
Rallybio Corp current P/E ratio is 2.05.
What is Rallybio Corp (RLYB) EBITDA?
Rallybio Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 44.99 million.
Does Rallybio Corp (RLYB) pay dividends?
No. Rallybio Corp does not pay a dividend.
When is Rallybio Corp (RLYB) next earnings report?
Rallybio Corp is expected to release its next earnings report on September 30, 2026.
What is Rallybio Corp (RLYB) beta (volatility) score?
Rallybio Corp has a beta of -0.714, indicating lower volatility than the overall market.
